HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that it will celebrate its 50th anniversary on September 13, 2025, marking five decades of advancing science and redefining possibilities for patients living with complex healthcare challenges. The company expresses its deep gratitude to patients, families, partners, and stakeholders worldwide who have been part of its journey.
Founded in 1975, JCR has grown from a pioneering biotech in Japan into a global biopharmaceutical company, with operations spanning the United States, Europe, and South America. Guided by its corporate philosophy — to create treatments that go beyond rare disease to solve the world’s most complex healthcare challenges — JCR has delivered transformative therapies by leveraging breakthrough platforms in regenerative medicine, recombinant protein engineering, and gene therapy.
“This milestone isn’t just about looking back at what we’ve achieved; it’s also about reaffirming our commitment to patients and charting an even bolder course for the future,” said Shin Ashida, Chairman, President, and CEO of JCR Pharmaceuticals. “At JCR, we have always prided ourselves on cutting-edge science and pushing boundaries to develop new and innovative technologies with the goal of developing treatments for complex healthcare challenges for those who need them most. We have been and will always be committed to working closely with patients, families, and physicians to inform our research and development programs so that our treatments make a real difference. Our mission is simple – to give people living with complex disease hope of a better future, and we look forward to continuing on this mission.”
To commemorate the anniversary, JCR will launch a series of initiatives throughout the year, including newspaper and transit campaigns, a dedicated anniversary logo and key creative, and a special webpage that highlights the company’s history, the people behind its innovations, and its vision for the decades ahead.
Visit the anniversary page here: https://www.jcrpharm.co.jp/50th/.
About the Anniversary Key Creative and Logo
The key creative features a beam of light illuminating JCR’s research and development journey — a symbol of the hope the company strives to bring to patients and communities — while the streamlined, linear design of the anniversary logo expresses 50 years of progress driven by a steadfast focus on patients.
As JCR enters its next chapter, the company remains steadfast in its commitment to stand with every patient, tackle the toughest challenges in medicine, and create transformative therapies that change lives.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: https://jcrpharm.com/.
Contacts
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
[email protected]
